Neurology

TeleSpecialists’ Groundbreaking AI-Focused Stroke Research Published in Frontiers in Stroke Journal

Collaborative research highlights the significance of AI-powered care coordination in acute stroke management FORT MYERS, Fla., July 24, 2024 /PRNewswire/…

1 year ago

Bausch Health Responds to Market Rumors

LAVAL, QC / ACCESSWIRE / July 24, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company") has become aware of…

1 year ago

AAIC 2024: Linus Health to Unveil Groundbreaking Research at Leading Alzheimer’s Conference

Life sciences platform enhanced to make cognitive assessments easier and more precise BOSTON, July 24, 2024 /PRNewswire/ -- Linus Health, a…

1 year ago

Transposon Announces Final Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia

TPN-101 treatment reduced the rate of decline of Vital Capacity by 50% compared to placebo after 24 weeks, an objective respiratory measure that correlates…

1 year ago

Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada

CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company…

1 year ago

Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium

Presentations will include an encore of the positive interim Phase 1/2 results presented in April at the 76th Annual American…

1 year ago

Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints

Skye introduces collaboration with Beacon Biosignals to evaluate potential impact of Nimacimab on sleep quality and sleep apneaSAN DIEGO, July…

1 year ago

ViewMind Applauded by Frost & Sullivan for Revolutionizing Brain Health Assessment and Care with Its Ocular Digital Phenotyping Solution

ViewMind's Ocular Digital Phenotyping solution is a holistic approach to brain and mental health that builds trust through technology, enabling…

1 year ago

Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

Group to Advise on the Application of Ovid’s Novel Pipeline Programs to Broader Disorders of the BrainNeurologists/epileptologists Dr. Imad Najm…

1 year ago

Dyslexia Treatment Market Size to hit $11.74 billion by 2031, growing at a CAGR of 6.4%, says Coherent Market Insights

BURLINGAME, Calif., July 22, 2024 /PRNewswire/ -- The global Dyslexia Treatment Market is projected to grow from USD 7.59 billion…

1 year ago